Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. RESEARCH AGREEMENTResearch Agreement • October 4th, 2013 • Karyopharm Therapeutics Inc. • Pharmaceutical preparations • New York
Contract Type FiledOctober 4th, 2013 Company Industry JurisdictionThis Research Agreement (this “Agreement”) is made as of the 18th day of July, 2011 (the “Effective Date”) by and between The Multiple Myeloma Research Foundation, Inc., a Connecticut non-stock corporation, with its principal place of business at 383 Main Avenue, 5th floor, Norwalk, CT 06851 (“MMRF”) and Karyopharm Therapeutics Inc., a Delaware corporation, with its principal place of business at 2 Mercer Road, Natick, MA 01760 (“Company”). MMRF and Company are sometimes hereinafter referred to individually as the “Party” and together as the “Parties”.
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. RESEARCH AGREEMENTResearch Agreement • September 5th, 2013 • Karyopharm Therapeutics Inc. • Pharmaceutical preparations • New York
Contract Type FiledSeptember 5th, 2013 Company Industry JurisdictionThis Research Agreement (this “Agreement”) is made as of the 18th day of July, 2011 (the “Effective Date”) by and between The Multiple Myeloma Research Foundation, Inc., a Connecticut non-stock corporation, with its principal place of business at 383 Main Avenue, 5th floor, Norwalk, CT 06851 (“MMRF”) and Karyopharm Therapeutics Inc., a Delaware corporation, with its principal place of business at 2 Mercer Road, Natick, MA 01760 (“Company”). MMRF and Company are sometimes hereinafter referred to individually as the “Party” and together as the “Parties”.